All Blogs / Industries / Medical / Pharmaceutical / New

Walgreens Plays to Win: Our Exclusive Analysis of 2017's Part D Preferred Pharmacy Networks

In a previous exclusive analysis (Preferred Pharmacy Networks Are Back in 85% of the 2017 Medicare Part D Plans), I highlighted how preferred pharmacy networks will dominate next year’s Medicare Part D prescription drug plans (PDP). Today, I examine pharmacy participation in the 2017 Part D preferred networks. Show More Summary

Drug Regulation in the Age of AMR – What We Know from our Experience with Tuberculosis

On the eve of the Union World Conference on Lung Health, Bev Stringer of Médecins Sans Frontières discusses how unregulated access to anti-tuberculosis treatments has contributed to the rise of multidrug-resistant TB. The World Heal...

Meet Me at FDA Public Hearing on Off-Label Promotion on November 9, 2016

I will be Speaking at FDA's Part 15 hearing on "Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products" on 9 November, 2016 (read "FDA May Have No Choice But to Allow Direct-to-Consumer Off-Label...Show More Summary

Real World Data for Competitive Advantage Summit

Real World Data for Competitive Advantage Summit December 13-14, 2016 • Philadelphia, PAVisit Website | Request BrochureAs advanced analytical methods and large data sets of treatment effectiveness become more readily available, the life science industry is primed to fine-tune its portfolio. Show More Summary

The Top Specialty Drug Distributors in 2015

The Big Three wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—will soon report their latest quarterly earnings. Expect specialty drugs to be a hot topic. About $134 billion in specialty drugs was sold via wholesale distribution in 2015. Show More Summary

Trauma, a Neglected Global Disease: A Call for Papers on Prevention, Management and the Acute Response to Injury

PLOS Medicine, the leading open access medical journal, publishes themed issues regularly to highlight and encourage progress in key areas of clinical research. As part of this program, the journal is now inviting submissions of

Employer Pharmacy Benefits in 2016: More Specialty Drug Cost-Shifting Means More Problems for Patients

It’s time for our annual analysis of the Kaiser/HRET 2016 Employer Health Benefits Survey, which you can read online for free. The survey delves into employer-sponsored health coverage at 2,000 companies. In the charts below, I summarize...Show More Summary

ACO Population Health Congress

ACO Population Health CongressDecember 8-9, 2016 | Tampa, FL’s ACO Population Health Congress conference offers payers and providers the opportunity to discover solutions for day-to-day challenges, improve the health of members and enhance models to quantify improvement and outcomes. Show More Summary

Follow the Vial: The Buy-and-Bill System for Distribution and Reimbursement of Provider-Administered Outpatient Drugs

By reader request, below is a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. It complements Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System, which focuses on patient-administered outpatient drugs. This post is adapted from Section 3.1.2. Show More Summary

Follow the Dollar: Measuring Who Profits From a Brand-Name Prescription

Now, here’s something I hope you’ll really like! I recently collaborated with Julie Appleby at Kaiser Health News (KHN) to explain the flow of funds between a pharmaceutical manufacturer and the patient. The resulting graphic (below)...Show More Summary

Specialty Product Data Strategies

CBI’s Specialty Product Data Strategies December 14, 2016 | Philadelphia, you seen the agenda for the Specialty Product Data Strategies meeting yet? Being held on December 14th in Philadelphia, this...Show More Summary

Copyright © 2015 Regator, LLC